Duality Biotherapeutics, Inc. 9606
HKEX · Hong Kong SAR China · Health Technology
HKD 201.80+0.20 (+0.10%)
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Duality Biotherapeutics has seen its share price fall sharply over the past year, yet the stock still screens as expensive on market multiples and only shows a mixed overall value profile. For investors, that raises the question of whether recent weakness has created an opening or whether the current price still builds in demanding expectations. The stock has declined 50.2% over the past year, which puts recent pricing under pressure despite the previous enthusiasm around the story. The...
DUALITYBIO Inc. (HKEX: 09606; "DualityBio" or the "Company") today announced that it has entered into a collaboration and license agreement with Genentech, a member of the Roche Group, to develop next-generation antibody-drug conjugates ("ADCs") built on the Company's proprietary DualityBio Unique Payload Antibody Conjugate ("DUPAC") platform.
Duality Biotherapeutics, Inc. (Hong Kong Stock Exchange Code: 09606.HK, hereinafter referred to as "DualityBio" or the "Company"), a leading global clinical-stage innovative biopharmaceutical company, today announced its first annual results since listing on April 15, 2025 (for the year ended December 31, 2025), providing a comprehensive update on its global clinical pipeline and corporate operations.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.